Asia Pacific Home Infusion Therapy Market

Market Overview

The Asia Pacific home infusion therapy market is expected to reach USD 10,055 million by 2030, with a CAGR of 10.2%.

An alternative to taking medication by mouth is infusion therapy, which is how the term is defined. The infusion process involves monitoring the administration of medication with the assistance of a sterile catheter inserted into a vein.

Home infusion therapy refers to giving an individual medication or biologicals through an intravenous or subcutaneous route while they live in their residence. The medication (such as antivirals or immune globulin, for example), the necessary piece of medical equipment (such as a pump), and the necessary medical supplies are required to carry out home infusion (for example, tubing and catheters). In a similar vein, nursing services are required to educate and train both the patient and the caregivers administering the infusion medications in the patient's home. Home infusion treatment frequently requires a significant contribution from visiting nurses. Typically, nurses will instruct the patient or the caregiver on how to self-administer the medication, educate the patient about the potential adverse effects of the treatment and the aims of therapy, and visit the patient occasionally to evaluate the infusion site and change the dressing. In most cases, the procedure of home infusion needs coordination among several different parties. These parties can include patients, physicians, hospital discharge planners, health plans, home infusion pharmacies, and, if necessary, home health organisations.

Market Dynamics

Market Drivers

Increasing Elderly Population

The elderly population is increasing. As the senior population grows, so will many medical conditions requiring long-term care. The growing preference of this age group for in-home healthcare services is expected to significantly increase demand for home infusion therapy products and services during the forecast period.

Chronic diseases that necessitate long-term care constitute a significant risk factor for ageing. Alzheimer's disease, dementia, diabetes, and other orthopaedic illnesses that impair movement are serious diseases associated with ageing (the risk of Alzheimer's disease approaches 50% for people aged 85 and up). People prefer home care as a result of the factor mentioned above. For example, nearly 70% of home healthcare patients are 65 or older.

Furthermore, the growing senior population in Asian countries and the presence of vast untapped opportunities in developing countries such as Japan and China are expected to drive market growth during the forecast period. For example, it is estimated that by 2050, around 79 per cent of the global population aged 60 and up will be living in developing countries.

A cost-effective alternate for the hospital stay

Home infusion is considered a more cost-effective alternative to an extended hospital stay or nursing home placement for patients with chronic diseases. Medication administration or infusion at home promotes faster recovery, a better experience, fewer complications, and lower costs. Home infusion therapy allows many patients to resume their daily activities, significantly improving their quality of life.

Market Restraints

The presence of a complex reimbursement framework as well as reimbursement cuts

One of the major factors driving the market growth is Medicare reimbursement for home healthcare providers and patients. Recent reimbursement cuts and rebasing of home health funding, on the other hand, are expected to hinder market growth during the forecast period. Medicare proposed cutting home health funding by 3.5 per cent per year from 2014 to 2017 in its draught of the Home Health Prospective Payment System (HPPS) rule for 2014. It is expected to significantly impact home health funding and limit patients' and senior citizens' ability to access clinically advanced and cost-effective home-based care. Rebasing has resulted in lower average margins, which have fallen from 8.6 per cent in 2014 to 5.0 per cent in 2017. Furthermore, the elimination of 170 ICD-9 codes from home healthcare reimbursement policies is expected to limit market growth during the forecast period.

Segmental Analysis

The Asia Pacific home infusion therapy market is classified into two types: products and services.

Further, it is divided into four product categories: infusion pumps, intravenous sets, iv cannulas, and needleless connectors. Infusion pumps accounted for the largest market share due to their widespread use in delivering fluids, including drugs and nutrition. Many infusion pumps are available, including enteral pumps, syringe pumps, multi-channel pumps, and peristaltic pumps.

On the other hand, needless connectors are expected to become more popular. The benefits of these devices, such as reduced bacterial contamination and increased protection against needlestick injuries, have aided the market's growth. As home healthcare becomes more common, the demand for syringes and ambulatory pumps rises.

Smart pumps with barcode technology help validate a patient's identity, preventing incorrect medicine from being administered to the patient. These pumps also notify healthcare workers if they choose an incorrect drug dosage. The introduction of technologically advanced infusion pumps, such as the CADD-Solis ambulatory infusion pump, is expected to drive infusion pump market growth during the forecast period.

Anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, and speciality pharmaceuticals are the application segments of the Asia Pacific home infusion therapy market.

The parenteral nutrition market is expected to grow significantly during the forecast period due to increasing government initiatives to raise awareness about parenteral nutrition.

Regional Analysis

The market is divided into India, Japan, China, Australia, South Korea, Malaysia, Indonesia, Singapore, Philippines & Thailand, based on country. The Asia-Pacific home infusion therapy market is expected to proliferate due to advanced healthcare infrastructure and increased patient awareness of home care benefits. Due to an increasing number of government steps to improve the country's overall healthcare system, Japan held the most significant share in the Asia-Pacific in 2021.

In Japan, for example, the government launched a home healthcare programme in 2018 to make home care solutions more viable. Furthermore, reimbursement for home-based parenteral, enteral nutrition, and pain management therapy has increased. As a result, the Japanese home infusion therapy market is expected to expand during the forecast period.

Recent Developments

• May 2022, Lilly's MounjaroTM (tirzepatide) injection has been approved by the FDA as the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.
• May 2022, Terumo Corporation announced that the indication for the Dexcom G6 CGM System in Japan has changed as of May 10, 2022. With this new indication, the Dexcom G6 CGM System will be the only real-time continuous glucose monitoring (RT-CGM) system in Japan that can be used primarily for day-to-day blood glucose management without a blood glucose metre.

Asia Pacific Home Infusion Therapy Market Segmentation

By Type

• Products
• Services

By Product

• Infusion Pumps
• Intravenous Sets
• IV Cannulas
• Needleless Connectors

By Application

• Anti-Infective
• Endocrinology
• Hydration Therapy
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific